The end of the beginning: Circulating tumor cells as a biomarker in castration-resistant prostate cancer

Journal of Clinical Oncology

Volumn 32, Issue 11, 2014, Pages 1104-1106

  Friedlander, Terence W ^a   Fong, Lawrence ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ATRASENTAN; DOCETAXEL; LACTATE DEHYDROGENASE; LENALIDOMIDE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; PYRROLIDINE DERIVATIVE; TAXOID;

CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; CLINICAL DECISION MAKING; EDITORIAL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); MALE; NOTE; PATHOLOGY; PROSTATE TUMOR; TUMOR EMBOLISM;

ANTINEOPLASTIC AGENTS; HUMANS; MALE; NEOPLASTIC CELLS, CIRCULATING; PROSTATIC NEOPLASMS; PYRROLIDINES; TAXOIDS;

EID: 84901852835     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.7307     Document Type: Editorial

References (16)

1. Ashworth TR: A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Med J Australia 14:146-149, 1869
2. Allard WJ, Matera J, Miller MC, et al: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:6897-6904, 2004 (Pubitemid 39383039)
3. Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781-791, 2004 (Pubitemid 39095313)
4. Cohen SJ, Punt CJ, Iannotti N, et al: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26:3213-3221, 2008
5. de Bono JS, Scher HI, Montgomery RB, et al: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302-6309, 2008
6. Scher HI, Heller G, Molina A, et al: Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J Clin Oncol 29:293s, 2011 (suppl; abstr LBA4517)
7. Vogelzang NJ, Petrylak D, Fizazi K, et al: Analysis of circulating tumor cells (CTCs) in a phase 3 study of docetaxel and prednisone (DP) with or without lenalidomide (LEN) in patients (pts) with castrate-resistant prostate cancer (CRPC): The MAINSAIL trial. Presented at European Cancer Congress 2013, Amsterdam, the Netherlands, September 27 through October 1, 2013 (abstr 23)
8. Goldkorn A, Ely B, Quinn DI, et al: Circulating tumor cell counts are prognostic of overall survival in Southwest Oncology Group trial S0421: A phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-1142, 2014
9. Halabi S, Small EJ, Kantoff PW, et al: Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21:1232-1237, 2003 (Pubitemid 46606398)
10. Scher H, Heller G, Molina A: Evaluation of a composite biomarker panel including circulating tumor cell (CTC) enumeration as a surrogate for survival in metastatic castration-resistant prostate cancer. European Cancer Congress 2013. Amsterdam, the Netherlands, September 27 through October 1, 2013 (abstr 2861)
11. Yu M, Bardia A, Wittner BS, et al: Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339:580-584, 2013
12. Alix-Panabières C, Brouillet JP, Fabbro M, et al: Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J Immunol Methods 299:177-188, 2005 (Pubitemid 40725934)
13. Warkiani ME, Guan G, Luan KB, et al: Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells. Lab on a Chip 1:128-137, 2014
14. Zheng S, Lin HK, Lu B, et al: 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdevices 13:203-213, 2011
15. Friedlander TW, Ngo VT, Dong H, et al: Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration resistant prostate cancer (mCRPC). Int J Cancer [epub ahead of print on October 25, 2013]
16. Marrinucci D, Bethel K, Kolatkar A, et al: Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol 9:016003, 20102